We serve Chemical Name:3,3-Dimethyldihydro-2,5-furandione CAS:17347-61-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3,3-Dimethyldihydro-2,5-furandione
CAS.NO:17347-61-4
Synonyms:2,5-Furandione, dihydro-3,3-dimethyl-;3,3-Dimethyldihydro-2,5-furandione;3,3-Dimethyldihydrofuran-2,5-dione;MFCD00022608;Dihydro-3,3-dimethyl-2,5-furandione;3,3-dimethyloxolane-2,5-dione;EINECS 241-371-0
Molecular Formula:C6H8O3
Molecular Weight:128.126
HS Code:2917190090
Physical and Chemical Properties:
Melting point:29-31 °C(lit.)
Boiling point:220.2±9.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.446
PSA:43.37000
Exact Mass:128.047348
LogP:-0.27
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 2,5-Furandione, dihydro-3,3-dimethyl- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 241-371-0 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,3-Dimethyldihydro-2,5-furandione Use and application,3,3-dimethyloxolane-2,5-dione technical grade,usp/ep/jp grade.
Related News: Aduhelm, however, is in a different league in terms of the number of potential patients and cost to the healthcare system. 3,3-Dimethyldihydro-2,5-furandione manufacturer As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 3,3-Dimethyldihydro-2,5-furandione supplier Aduhelm, however, is in a different league in terms of the number of potential patients and cost to the healthcare system. 3,3-Dimethyldihydro-2,5-furandione vendor This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved. 3,3-Dimethyldihydro-2,5-furandione factory Aduhelm, however, is in a different league in terms of the number of potential patients and cost to the healthcare system.
